Compare LFCR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFCR | RCKT |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.8M | 239.3M |
| IPO Year | 1996 | 2014 |
| Metric | LFCR | RCKT |
|---|---|---|
| Price | $6.37 | $2.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $6.28 | ★ $8.58 |
| AVG Volume (30 Days) | 430.4K | ★ 2.0M |
| Earning Date | 11-04-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $557,559,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.47 | $915.60 |
| P/E Ratio | ★ N/A | $3.95 |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $3.63 | $2.17 |
| 52 Week High | $8.98 | $5.45 |
| Indicator | LFCR | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 60.56 | 47.85 |
| Support Level | $6.32 | $2.17 |
| Resistance Level | $6.50 | $2.73 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 21.95 | 64.00 |
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.